Todd Davis/LinkedIn
Sep 13, 2024, 14:34
Todd Davis: Ligand’s announcement on the FILSPARI full FDA approval
Todd Davis, CEO at Ligand Pharmaceuticals, shared on LinkedIn:
“We have had significant positive momentum across the Ligand Pharmaceuticals royalty portfolio in recent months. Yesterday marks another critical milestone with the full FDA approval for FILSPARI (sparsentan), developed by our long-term partner Travere Therapeutics for the treatment of IgA nephropathy, a rare progressive kidney disease that affects approximately 150,000 in the U.S. FILSPARI has become a key part of our royalty portfolio at Ligand which now includes 12 key commercial-stage products including treatments for cancer, COPD, kidney disease, and other rare conditions that impact billions of people globally.”
Read further.
Source: Todd Davis/Linkedin
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 18, 2024, 22:22
Nov 18, 2024, 22:02
Nov 18, 2024, 21:55
Nov 18, 2024, 20:54
Nov 18, 2024, 18:36
Nov 18, 2024, 18:32